Connect with us

CBD News

MediPharm Labs Receives a New Cannabis Research License for Human Consumption

Denis Mariti

Published

on

MediPharm-Labs-Corp-Receives-A-New-Cannabis-Research-License
- Ad -

As the marijuana industry continues to expand, it is facing post-legalization struggles due to the increased supply of cannabis-infused products into the market. Licensed pharmaceutical companies and cannabis producers are seeking new ways of increasing cannabis-products trial and consequently, consumers to make profits.

Health Canada issued the final regulations on vapes and edibles early this year. These legalized “cannabis 2.0” products are expected to be available to consumers by December 2019. Among the newly legalized marijuana products includes cannabis-infused beverages which are notably the leading product in the overall marijuana sales in the market.

Today, October 31, 2019, MediPharm Labs Corp. was granted a cannabis research license through its subsidiary MediPharm Labs Inc. The Barrie, Ontario based company will begin quality assurance testing at Barrie.

Human sensory evaluation trials are expected to officially commence immediately after the research is complete. This will involve trying the smell and tastes of various marijuana products topicals, edibles, extracts, and distillates. The study will aim at finding out the effects of cannabis consumption on the human body. With the finding of the research, MediPharm will be better placed to meet consumer demands and preferences for different products.

According to Pat McCutcheon, the CEO at MediPharm, the acquisition of the new research license for testing terpenes to gauge reactions will be a game-changer for the company. This coincides with the legalization of cannabis topicals, cannabis-infused beverages, and edibles in Canada.

“It will help us improve our products for safe human consumption. Testing for sensory properties and scientific studies is what gives us a competitive edge,” he said.

Although MediPharm Labs stock remains higher compared to other companies in the cannabis industry, the company has witnessed a drop since summer from $5.40 in August to $3.50 this morning. Stock prices have dropped across the entire industry. The arrival of the new products is what will save the industry from suffering huge losses.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com